Impact of Tertiary Lymphoid Structures on Glioma Progression

Tertiary Lymphoid Structures: Definition and Significance

Tertiary lymphoid structures (TLSs) are ectopic lymphoid formations that arise in chronically inflamed tissues, including various solid tumors, and they play a pivotal role in modulating immune responses. Unlike secondary lymphoid organs (SLOs), such as lymph nodes, TLSs lack a defined anatomical structure but still facilitate critical immune functions, including the recruitment and activation of T and B lymphocytes (Chen et al., 2023). Their formation is indicative of an ongoing immune response against tumors, suggesting potential therapeutic implications in cancer treatment.

The presence of TLSs has been linked to improved patient outcomes in several malignancies, as they can enhance anti-tumor immunity by fostering a local immune environment conducive to T cell activation and antibody production (Sautes-Fridman et al., 2019). However, in gliomas, the role of TLSs is complex and can vary significantly between individuals.

Immune Microenvironment of Gliomas and TLS Formation

The immune microenvironment of gliomas is characterized by a heterogeneous assembly of immune cells, including tumor-infiltrating lymphocytes (TILs), macrophages, and microglia. In glioblastomas (GBMs), which are the most aggressive form of glioma, the immune landscape is often dominated by immunosuppressive factors that inhibit effective anti-tumor immune responses (Zhao et al., 2024).

The formation of TLSs within the glioma microenvironment can be influenced by several factors, including the presence of inflammatory cytokines, the local hypoxic environment, and the permeability of the blood-brain barrier (BBB) (Louveau et al., 2015). Key chemokines, such as CCL19 and CXCL13, are essential for TLS development, as they facilitate the recruitment of immune cells to the tumor site (Cupedo et al., 2010). Furthermore, the interaction between lymphoid tissue inducer cells and lymphoid tissue organizers is critical for TLS maturation and function (Randall, 2010).

Characteristics of TLSs in Gliomas Compared to Other Tumors

TLSs in gliomas exhibit distinct characteristics compared to those in other solid tumors. Research indicates that glioma-associated TLSs are often immature, with a limited number of germinal centers and a predominance of regulatory T cells (Tregs) (He et al., 2022). In contrast, TLSs in tumors like breast and colorectal cancer are typically more developed, showing increased T and B cell zones and functional high endothelial venules (HEVs) (Wang et al., 2021).

The spatial distribution of TLSs also varies significantly. In gliomas, TLSs are predominantly located at the tumor margins or peritumoral areas, while in other cancers, they are often found within the tumor core (Chen et al., 2023). This difference may affect the efficacy of immune responses and therapeutic interventions, as TLSs within the tumor may provide a more favorable microenvironment for immune cell activation compared to those at the periphery (Zhao et al., 2024).

Role of TLSs in Glioma Immunotherapy and Treatment Response

The presence of TLSs in gliomas has been correlated with patient prognosis and response to immunotherapy. Studies suggest that higher densities of TLSs are associated with improved survival outcomes in patients (Ding et al., 2022). For instance, TLSs facilitate the recruitment of cytotoxic T cells, which are crucial for effective anti-tumor immunity. When combined with immune checkpoint inhibitors (ICIs), TLSs may enhance therapeutic efficacy by creating a more immunologically active tumor environment (Thommen & Schumacher, 2022).

However, the dual role of TLSs must be acknowledged, as they can also contribute to tumor immune escape mechanisms. Glioma cells may exploit TLSs to foster immune tolerance, particularly through the accumulation of Tregs that inhibit effector T cell functions (Pang et al., 2022). This highlights the necessity for a nuanced understanding of TLS dynamics in glioma treatment strategies.

Future Perspectives on Targeting TLSs for Glioma Therapy

The potential for targeting TLSs in glioma therapy presents exciting opportunities. Future research should focus on enhancing TLS formation through the administration of immunomodulatory agents, such as LIGHT, which has shown promise in promoting TLS development and improving T cell responses in glioma models (Ramachandran et al., 2023). Additionally, the integration of novel therapies that modulate the immune microenvironment, such as STING agonists, could further optimize TLS functions and improve patient outcomes (He et al., 2024).

Developing personalized strategies that leverage the presence of TLSs to enhance immunotherapy responses is crucial. This may involve identifying patients with high TLS density for more aggressive immunotherapeutic approaches, while also exploring strategies to inhibit the immunosuppressive effects of TLSs in glioma patients (Zhao et al., 2024).

Frequently Asked Questions (FAQ)

What are tertiary lymphoid structures (TLSs)?
TLSs are ectopic lymphoid formations that arise in response to chronic inflammation and play a critical role in modulating immune responses, particularly within tumors.

How do TLSs affect glioma progression?
TLSs can enhance anti-tumor immunity but may also contribute to immune escape mechanisms, making their role in glioma progression complex and multifaceted.

Can TLSs predict treatment response in gliomas?
Yes, higher densities of TLSs have been associated with improved survival outcomes and better responses to immunotherapy in glioma patients.

What future research directions are being considered for TLSs in glioma therapy?
Future research aims to enhance TLS formation through immunomodulatory therapies and develop personalized treatment strategies that utilize the presence of TLSs to improve patient outcomes.

References

1. Chen, J., Yang, Y., Luan, S., Xu, W., & Gao, Y. (2023). Tertiary lymphoid structures in gliomas: impact on tumour immunity and progression. Journal of Translational Medicine, 21(1), 1-18. doi:10.1186/s12967-025-06510-6
2. Sautes-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019). Tertiary lymphoid structures in the era of cancer immunotherapy. Nature Reviews Cancer, 19(5), 307-325. doi:10.1038/s41568-019-0144-6
3. Zhao, W., Lu, J., Tian, X., & Xu, Q. (2024). Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma. Frontiers in Immunology, 14, 1166497. doi:10.3389/fimmu.2023.1166497
4. Ding, G. Y., Ma, J. Q., Yun, J. P., Chen, X., Ling, Y., Zhang, S., Shi, J. Y., Chang, Y. Q., Ji, Y., & Wang, X. Y. (2022). Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J Hepatol, 76(4), 608-618. doi:10.1016/j.jhep.2021.10.030
5. Thommen, D. S., & Schumacher, T. N. (2022). Tertiary lymphoid structures in cancer. Science, 375(6579), eabf9419. doi:10.1126/science.abf9419
6. Pang, L., Khan, F., Heimberger, A. B., & Chen, P. (2022). Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. Trends in Cancer, 8(5), 839-854. doi:10.1016/j.trecan.2022.04.010
7. Ramachandran, M., Vaccaro, A., van de Walle, T., Georganaki, M., Lugano, R., Vemuri, K., & Kemeny, H. R. (2023). Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell, 41(11), 1134-1151. doi:10.1016/j.ccell.2023.04.010
8. He, W., Zhang, D., Liu, H., Chen, T., Xie, J., Peng, L., Zheng, X., Xu, B., Li, Q., & Jiang, J. (2022). The high level of tertiary lymphoid structure is correlated with superior survival in patients with advanced gastric cancer. Frontiers in Oncology, 10, 980. doi:10.3389/fonc.2020.00980
9. Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., & Lee, K. S. (2015). Structural and functional features of central nervous system lymphatic vessels. Nature, 523(7560), 337-341. doi:10.1038/nature14432
10. Cupedo, T., & Mebius, R. E. (2010). Role of chemokines in the development of secondary and tertiary lymphoid tissues. Seminars in Immunology, 22(4), 243-248. doi:10.1016/j.smim.2010.06.012
11. Randall, T. D. (2010). Bronchus-associated lymphoid tissue (BALT) structure and function. Advances in Immunology, 107, 187-241. doi:10.1016/B978-0-12-381300-8.00007-1
12. Sautes-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019). Tertiary lymphoid structures in the era of cancer immunotherapy. Nature Reviews Cancer, 19(5), 307-325. doi:10.1038/s41568-019-0144-6
13. Zhao, W., Lu, J., Tian, X., & Xu, Q. (2024). Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma. Frontiers in Immunology, 14, 1166497. doi:10.3389/fimmu.2023.1166497
14. Ding, G. Y., Ma, J. Q., Yun, J. P., Chen, X., Ling, Y., Zhang, S., Shi, J. Y., Chang, Y. Q., Ji, Y., & Wang, X. Y. (2022). Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J Hepatol, 76(4), 608-618. doi:10.1016/j.jhep.2021.10.030
15. Thommen, D. S., & Schumacher, T. N. (2022). Tertiary lymphoid structures in cancer. Science, 375(6579), eabf9419. doi:10.1126/science.abf9419
16. Pang, L., Khan, F., Heimberger, A. B., & Chen, P. (2022). Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. Trends in Cancer, 8(5), 839-854. doi:10.1016/j.trecan.2022.04.010
17. Ramachandran, M., Vaccaro, A., van de Walle, T., Georganaki, M., Lugano, R., Vemuri, K., & Kemeny, H. R. (2023). Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell, 41(11), 1134-1151. doi:10.1016/j.ccell.2023.04.010
18. He, W., Zhang, D., Liu, H., Chen, T., Xie, J., Peng, L., Zheng, X., Xu, B., Li, Q., & Jiang, J. (2022). The high level of tertiary lymphoid structure is correlated with superior survival in patients with advanced gastric cancer. Frontiers in Oncology, 10, 980. doi:10.3389/fonc.2020.00980